At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,012 enrolled
Drug / intervention
RPC1063 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
In Brief
A Phase 3 clinical trial evaluating RPC1063 and Placebo for Ulcerative Colitis. Completed, enrolled 1,012 participants across 372 sites in 30 countries.
Detailed Summary
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesArgentina, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Croatia, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Moldova, Netherlands, New Zealand, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJun 2015
Primary CompletionMar 2020
Study CompletionJun 2020
TodayJul 2026
First PostedMay 6, 2015
Enrollment StartJun 17, 2015
Primary CompletionMar 27, 2020
Study CompletionJun 17, 2020
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 11.2 years ago
Interventions
RPC1063drug
Placebodrug